Pub. Date : 2005 Jul
PMID : 16422846
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. | Nitrates | phosphodiesterase 5A | Homo sapiens |
2 | Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction. | Nitrates | phosphodiesterase 5A | Homo sapiens |
3 | Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction. | Nitrates | phosphodiesterase 5A | Homo sapiens |
4 | MAIN OUTCOME MEASURES: Discontinuation of oral nitrates to facilitate subsequent use of PDE5 therapy. | Nitrates | phosphodiesterase 5A | Homo sapiens |
5 | Forty-nine of the 52 men no longer taking nitrates were treated with a PDE5 inhibitor which was effective in 22 out of 26 (85%) patients who have completed follow-up. | Nitrates | phosphodiesterase 5A | Homo sapiens |
6 | CONCLUSION: Oral nitrates can be discontinued in the presence of continuing beta-blockade and/or calcium antagonist therapy in stable coronary disease patients with ED to allow for the safe use of PDE5 inhibitors. | Nitrates | phosphodiesterase 5A | Homo sapiens |